Cramer honestly believes that regular investors can outperform the broad market every day, including today, simply by following this strategy.» Read More
*Teva, Ranbaxy to pay $150,000 each to settle with New York State. Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition.
Feb 18- The New York Attorney General and the U.S. units of Ranbaxy Laboratories Ltd and Teva Pharmaceutical Industries Ltd have settled claims that an agreement between the two drugmakers unlawfully restricted competition. Teva and Ranbaxy will pay the New York state $300,000 and have agreed to refrain from similar agreements in the future.
Some of Thursday's midday movers:
Markets are in wait-and-see mode ahead of Friday's jobs report, but there are a few events Thursday that could sway the market's direction.
Talking Squawk, the "Squawk Box" blog, provides tidbits, insights and sarcastic reflections on the WEEK THAT WAS and the WEEK TO COME.
JERUSALEM, Jan 26- Investors in Israel's Teva Pharmaceutical Industries largely shrugged off a negative opinion from the European Medicines Agency on multiple sclerosis drug laquinimod in the belief that it will be reformulated.
Jan 21- Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug. Analysts are skeptical of Amarin's ability to run a profitable business without the new indication of its only approved drug, Vascepa.
Jan 21- NuPathe Inc said it terminated its takeover deal with Endo Health Solutions Inc and accepted an offer from Israel's Teva Pharmaceutical Industries Ltd. Teva offered to buy the neurology drugs maker on Jan. 8 for $114 million plus milestone payments related to its Zecuity migraine treatment.
Jan 14- A federal judge said Teva Pharmaceutical Industries Ltd did not infringe five patents related to the painkiller OxyContin, helping push shares of the world's largest generic drug manufacturer up 6.7 percent on Tuesday.
Jan 14- Teva Pharmaceutical Industries Ltd said on Tuesday it is "completely confident" the new version of its flagship multiple sclerosis drug, Copaxone, which features less frequent dosing, will be approved in the United States in the near future.
*Forest Labs shares rise; will buy peer Aptalis. NEW YORK, Jan 8- The Dow and the S&P 500 declined modestly on Wednesday as investors awaited the release of minutes from the Federal Reserve's most recent policy meeting, while Micron's strong results helped boost the Nasdaq.
Some of Wednesday's midday movers:
Jan 8- Israel's Teva Pharmaceutical Industries Ltd offered to buy U.S. neurology drugs maker NuPathe Inc for $114 million plus milestone payments related to NuPathe's Zecuity migraine treatment.
Jan 8- NuPathe Inc said it received a buyout offer from Israel's Teva Pharmaceutical Industries Ltd for $114 million plus milestone payments related to NuPathe's Zecuity migraine treatment.
*FDA asks for more clinical trials on Lemtrada. The FDA also demanded Sanofi carry out further clinical trials using different designs and methods prior to approval, Sanofi said.
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Take a look at some of Friday's midday movers: Twitter, Textron, Sprint
Some of the names on the move ahead of the open.
Jim Cramer often advocates viewing a sell-off as opportunity. Often, but not always.
Dec 17- Pfizer Inc on Tuesday said it would allow Teva Pharmaceutical Industries to sell generic forms of its Viagra anti-impotence treatment in the United States beginning in late 2017, in a settlement of longstanding patent litigation between the two drugmakers.